181 related articles for article (PubMed ID: 35608260)
1. Crovalimab for treatment of patients with paroxysmal nocturnal haemoglobinuria and complement C5 polymorphism: Subanalysis of the phase 1/2 COMPOSER study.
Nishimura JI; Usuki K; Ramos J; Ichikawa S; Buri M; Kiialainen A; Sostelly A; Peffault de Latour R; Paz-Priel I; Röth A
Br J Haematol; 2022 Aug; 198(3):e46-e50. PubMed ID: 35608260
[No Abstract] [Full Text] [Related]
2. Crovalimab treatment in patients with paroxysmal nocturnal haemoglobinuria: Long-term results from the phase I/II COMPOSER trial.
Röth A; Ichikawa S; Ito Y; Kim JS; Nagy Z; Obara N; Panse J; Schrezenmeier H; Sica S; Soret J; Usuki K; Yoon SS; Balachandran N; Buri M; Lundberg P; Patel H; Shinomiya K; Sostelly A; Nishimura JI
Eur J Haematol; 2023 Aug; 111(2):300-310. PubMed ID: 37321625
[TBL] [Abstract][Full Text] [Related]
3. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria.
Röth A; Nishimura JI; Nagy Z; Gaàl-Weisinger J; Panse J; Yoon SS; Egyed M; Ichikawa S; Ito Y; Kim JS; Ninomiya H; Schrezenmeier H; Sica S; Usuki K; Sicre de Fontbrune F; Soret J; Sostelly A; Higginson J; Dieckmann A; Gentile B; Anzures-Cabrera J; Shinomiya K; Jordan G; Biedzka-Sarek M; Klughammer B; Jahreis A; Bucher C; Peffault de Latour R
Blood; 2020 Mar; 135(12):912-920. PubMed ID: 31978221
[TBL] [Abstract][Full Text] [Related]
4. Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 Inhibitors.
Nishimura JI; Soubret A; Arase N; Buatois S; Hotta M; Charoin JE; Ito Y; Sreckovic S; Takamori H; Bucher C; Ueda Y; Hernández-Sánchez J; Gotanda K; Jordan G; Shinomiya K; Ramos J; Kim JS; Panse J; de Latour RP; Röth A; Morii E; Schrezenmeier H; Isaka Y; Sica S; Kanakura Y; Yoon SS; Kinoshita T; Paz-Priel I; Sostelly A
Clin Pharmacol Ther; 2023 Apr; 113(4):904-915. PubMed ID: 36660902
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of patients with paroxysmal nocturnal hemoglobinuria on a complement inhibitor.
Kulasekararaj AG; Brodsky RA; Hill A
Am J Hematol; 2021 Jul; 96(7):E232-E235. PubMed ID: 33780028
[No Abstract] [Full Text] [Related]
6. [Eculizumab in paroxysmal nocturnal hemoglobinuria].
Socié G; Varoqueaux N; Peffault de Latour R
Med Sci (Paris); 2009 Dec; 25(12):1126-9. PubMed ID: 20035691
[TBL] [Abstract][Full Text] [Related]
7. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study.
Liu H; Xia L; Weng J; Zhang F; He C; Gao S; Jia J; Chang AC; Lundberg P; Shi J; Sima CS; Sostelly A; Sreckovic S; Xiao Z; Zhang Z; Fu R
Am J Hematol; 2023 Sep; 98(9):1407-1414. PubMed ID: 37421604
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Hill A
Clin Adv Hematol Oncol; 2005 Nov; 3(11):849-50. PubMed ID: 16491626
[No Abstract] [Full Text] [Related]
10. Genetic variants of C5 and polymorphisms of C3 in Chinese patients with paroxysmal nocturnal hemoglobinuria.
Du Y; Zhang Q; Han B
Int J Lab Hematol; 2016 Aug; 38(4):e84-5. PubMed ID: 27307199
[No Abstract] [Full Text] [Related]
11. Pharmacokinetic and pharmacodynamic effects of ravulizumab and eculizumab on complement component 5 in adults with paroxysmal nocturnal haemoglobinuria: results of two phase 3 randomised, multicentre studies.
Peffault de Latour R; Brodsky RA; Ortiz S; Risitano AM; Jang JH; Hillmen P; Kulagin AD; Kulasekararaj AG; Rottinghaus ST; Aguzzi R; Gao X; Wells RA; Szer J
Br J Haematol; 2020 Nov; 191(3):476-485. PubMed ID: 32449174
[TBL] [Abstract][Full Text] [Related]
12. Eculizumab for paroxysmal nocturnal haemoglobinuria.
Parker C
Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of a PNH patient non-responsive to eculizumab with the novel complement C5 inhibitor coversin (nomacopan).
Schols S; Nunn MA; Mackie I; Weston-Davies W; Nishimura JI; Kanakura Y; Blijlevens N; Muus P; Langemeijer S
Br J Haematol; 2020 Jan; 188(2):334-337. PubMed ID: 31840801
[No Abstract] [Full Text] [Related]
14. [Paroxysmal nocturnal hemoglobinuria].
Geffray L
Rev Med Interne; 2008 Nov; 29(11):957-61. PubMed ID: 18801601
[No Abstract] [Full Text] [Related]
15. Eculizumab in paroxysmal nocturnal haemoglobinuria.
Charneski L; Patel PN
Drugs; 2008; 68(10):1341-6. PubMed ID: 18578555
[TBL] [Abstract][Full Text] [Related]
16. Improving renal outcomes in chronic anemia: learning from paroxysmal nocturnal hemoglobinuria.
Guasch A
Am J Hematol; 2010 Aug; 85(8):551-2. PubMed ID: 20658585
[No Abstract] [Full Text] [Related]
17. Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria.
Merrill SA; Brodsky RA
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):371-376. PubMed ID: 30504334
[TBL] [Abstract][Full Text] [Related]
18. Characterization of multivalent complexes formed in the presence of more than one conventional antibody to terminal complement component C5.
Cone J; Kimmel L; Zhang Y; Johnson K; Sheridan D; Tamburini P
PLoS One; 2023; 18(4):e0284502. PubMed ID: 37079521
[TBL] [Abstract][Full Text] [Related]
19. [The C5 gene polymorphism in patients with PNH].
Nishimura J; Kanakura Y
Rinsho Ketsueki; 2015 Feb; 56(2):103-10. PubMed ID: 25765788
[TBL] [Abstract][Full Text] [Related]
20. [Antibody therapy for paroxysmal nocturnal hemoglobinuria].
Nishimura JI
Rinsho Ketsueki; 2020; 61(8):929-936. PubMed ID: 32908057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
